Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
31.75(c) 31.75(c) 31.75(c) 31.75(c) 31.75(c) Last
220 0 0 1 030 0 Volume
0.00% 0.00% 0.00% 0.00% 0.00% Change
More quotes
Financials ( GBP)
Sales 2017 0,66 M
EBIT 2017 -13,3 M
Net income 2017 -13,1 M
Finance 2017 2,49 M
Yield 2017 -
Sales 2018 5,47 M
EBIT 2018 -13,9 M
Net income 2018 -13,8 M
Finance 2018 1,42 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 20,3x
EV / Sales2018 2,64x
Capitalization 15,9 M
More Financials
Company
Realm Therapeutics Plc engages in the development and provision of water-based clean technology decontamination solutions.It operates through the following Supermarket Retail and Health Science segments.The Supermarket Retail segment provides products extending the shelf life of fresh produce.The... 
More about the company
Surperformance© ratings of Realm Therapeutics PLC
Trading Rating : - Investor Rating :
More Ratings
Latest news on REALM THERAPEUTICS PLC
03/23 REALM THERAPEUTICS : 2016 Loss Widens As It Progresses Pipeline
02/28 REALM THERAPEUTICS : FDA permits PR022 to Proceed to Phase 2 Trial
02/28 REALM THERAPEUTICS : Phase II Trials Of PR022 Cleared By US FDA
2016 PURICORE : Change of name
2016 PURICORE : Lead Candidates See Progress As It Plans Name Change
2016 PURICORE : Offloads Supermarket Retail Arm, Interim Loss Widens
2016 PURICORE : Granted Two US Patents For Skin Disorder Therapy Production
2016 PURICORE : To Submit New Drug Application For PR022 To FDA In 2017
2016 PURICORE : To Stop Selling ProduceFresh Until Registered As Pesticide
2016 PURICORE : Strategic Review and Trading Update
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Christian Peters Chief Medical Officer
Joseph William Birkett Senior Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC5.83%21
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG6.92%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results